[Federal Register: February 15, 2008 (Volume 73, Number 32)]
[Page 8885]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]



Food and Drug Administration

Anti-Infective Drugs Advisory Committee; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.


SUMMARY: The Food and Drug Administration (FDA) is announcing an 
amendment to the notice of a meeting of the Anti-Infective Drugs 
Advisory Committee. This meeting was announced in the Federal Register 
of January 11, 2008 (73 FR 2055). The amendment is being made to 
reflect a change in the Date and Time and Agenda portions of the 
document. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Sohail Mosaddegh, Center for Drug 
Evaluation and Research (HFD-21), Food and Drug Administration, 5600 
Fishers Lane, Rockville, MD 20857, 301-827-7001, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), code 3014512530. Please call the Information Line 
for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the Federal Register of January 11, 2008, 
FDA announced that a meeting of the Anti-Infective Drugs Advisory 
Committee would be held on February 27 and 28, 2008. On page 2056, in 
the first column, the Date and Time and Agenda portions are amended to 
read as follows:
    Date and Time: The meeting will be held on February 27, 2008, from 
8 a.m. to 5 p.m.
    Agenda: On February 27, 2008, the committee will discuss new drug 
application (NDA) 022-110, telavancin powder for reconstitution and 
intravenous administration, Theravance, Inc., proposed for the 
treatment of complicated skin and skin structure infection.
    This notice is issued under the Federal Advisory Committee Act 
(U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

    Dated: February 11, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8-2824 Filed 2-14-08; 8:45 am]